EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Longitudinal Clinical Progression in X‐Linked Adrenoleukodystrophy: The AMNL Scoring System

Eda G Kabak iD, Cecilie Videbaek, Marije M C Voermans, Björn M van Geel, Keith van Haren iD, Stephan Kemp, Diederik van de Beek, Marc Engelen

Annals of the Child Neurology Society · 2026-09 · 4 (3) · 219-226

DOI: 10.1002/cns3.70084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Child Neurology Society, online erschienen am 04.08.2026. Verfasst von Eda G Kabak und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Neurology and Pediatric Neurology, Emma Children's Hospital, Amsterdam Leukodystrophy Center, Amsterdam University Medical Center, Ams…. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The current clinical nomenclature for individuals with ABCD1 gene dysfunction is often uninformative. The disorder was initially described as a combination of adrenal insufficiency and leukodystrophy, leading to the widespread use of “X‐linked adrenoleukodystrophy” (ALD). However, this term is inaccurate for individuals who never develop these features. ABCD1 dysfunction can cause various symptom complexes: adrenal insufficiency, myelopathy, neuropathy, and leukodystrophy, which may occur consecutively, simultaneously, or not at all.

Methods

We developed an intuitive annotation system to precisely convey phenotype status for individuals with ABCD1 dysfunction. The “AMNL score” assesses the presence and severity of [A]drenal insufficiency, [M]yelopathy, [N]europathy, and [L]eukodystrophy, with scores ranging from 0 (no symptoms) to 3 (severe) per domain.

Results

Applied to initial clinical encounters with 101 Dutch patients and 30 patients from the California newborn screening (NBS) program, the system identified 33 unique presentations. The most common was isolated mild myelopathy (A0M1N0L0). Including predominantly asymptomatic NBS newborns (mostly A0M0NUL0) broadened the spectrum and highlighted the need for precise classification across ages. Longitudinal use over 2 years in 99 Dutch patients showed progression in one or more domains in 41.4%, most often worsening myelopathy. In the NBS cohort (median follow‐up: 3.5 years; range: 0.3–12.2), most patients showed no myelopathy or leukodystrophy, though adrenal involvement was detected in half. Initial inter‐rater reliability was high ( α = 0.996).

Interpretation

The AMNL score's ability to quantify domain‐specific changes over time makes it valuable for monitoring disease evolution in clinical practice and research.

Schlagwörter

Stichwörter der Autor:innen

ABCD‐1 deficiencyALDAMNL scoreleukodystrophymyelopathy

Autor:innen und Institutionen

  • Departments of Neurology and Pediatric Neurology, Emma Children's Hospital, Amsterdam Leukodystrophy Center, Amsterdam University Medical Center, Amsterdam Neuroscience University of Amsterdam Amsterdam the Netherlands.
  • Department of Neurology Stanford University School of Medicine Palo Alto California USA.
  • Department of Pediatrics and Clinical Genetics Centre for Inherited Metabolic Diseases, Copenhagen University Hospital, Rigshospitalet Copenhagen Denmark.
  • Noordwest Ziekenhuisgroep Alkmaar the Netherlands.
  • Laboratory Genetic Metabolic Diseases, Department of Laboratory Medicine, Amsterdam University Medical Center, Amsterdam Gastroenterology Endocrinology Metabolism University of Amsterdam Amsterdam the Netherlands.
  • Department of Neurology, Amsterdam University Medical Center, University of Amsterdam Amsterdam Neuroscience Amsterdam the Netherlands.

ORCID-Profile: Eda G Kabak, Keith van Haren

Zitieren

APA

Kabak, E. G., Videbaek, C., Voermans, M. M. C., van Geel, B. M., van Haren, K., Kemp, S., van de Beek, D., & Engelen, M. (2026). Longitudinal Clinical Progression in X‐Linked Adrenoleukodystrophy: The AMNL Scoring System. Annals of the Child Neurology Society, 4(3), 219-226. https://doi.org/10.1002/cns3.70084

Vancouver

Kabak EG, Videbaek C, Voermans MMC, van Geel BM, van Haren K, Kemp S, et al. Longitudinal Clinical Progression in X‐Linked Adrenoleukodystrophy: The AMNL Scoring System. Annals of the Child Neurology Society. 2026;4(3):219-226. doi:10.1002/cns3.70084

BibTeX
@article{Kabak2026,
  author = {Kabak, Eda G and Videbaek, Cecilie and Voermans, Marije M C and van Geel, Björn M and van Haren, Keith and Kemp, Stephan and van de Beek, Diederik and Engelen, Marc},
  title = {Longitudinal Clinical Progression in X‐Linked Adrenoleukodystrophy: The AMNL Scoring System},
  journal = {Annals of the Child Neurology Society},
  year = {2026},
  volume = {4},
  number = {3},
  pages = {219--226},
  doi = {10.1002/cns3.70084}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche